	US 12,275,964 B2
	Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
Jennifer A. Doudna, Berkeley, CA (US); Benjamin L. Oakes, El Cerrito, CA (US); Natalia Orlova, Carrboro, NC (US); and Junjie Liu, Berkeley, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Appl. No. 17/266,270
Filed by The Regents of the University of California, Oakland, CA (US)
PCT Filed Aug. 21, 2019, PCT No. PCT/US2019/047488 § 371(c)(1), (2) Date Feb. 5, 2021, PCT Pub. No. WO2020/041456, PCT Pub. Date Feb. 27, 2020.
Claims priority of provisional application 62/721,528, filed on Aug. 22, 2018.
Prior Publication US 2021/0309981 A1, Oct. 7, 2021
Int. Cl. C12N 9/22 (2006.01); A61K 9/127 (2006.01); A61K 31/7088 (2006.01); A61K 38/46 (2006.01); C12N 15/11 (2006.01); C12N 15/88 (2006.01); C12N 15/90 (2006.01); C12Q 1/6841 (2018.01); C12Q 1/70 (2006.01)

CPC C12N 9/22 (2013.01) [A61K 9/127 (2013.01); A61K 31/7088 (2013.01); A61K 38/465 (2013.01); C12N 15/11 (2013.01); C12N 15/88 (2013.01); C12N 15/90 (2013.01); C12N 15/907 (2013.01); C12Q 1/6841 (2013.01); C12Q 1/701 (2013.01); C07K 2319/09 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)]

23 Claims

1. A variant CasX polypeptide comprising 85% or more identity to SEQ ID NO: 1 or 2, wherein amino acids 863-873 of SEQ ID NO: 1 or amino acids 850-860 of SEQ ID NO: 2 are replaced with a glycine polymer, a glycine-serine polymer, a glycine-alanine polymer, or an alanine-serine polymer, wherein the variant CasX polypeptide retains DNA binding activity and wherein the variant CasX polypeptide does not exhibit double-stranded DNA cleavage activity.